Method of Providing Disease-Specific Binding Molecules and Targets

Abstract

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and / or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

Description

RELATED APPLICATIONS[0001]U.S. patent application Ser. No. 12 / 522,031, which is the National Stage of International Application No. PCT / EP2008 / 000053, filed Jan. 7, 2008, U.S. Provisional Application No. 60 / 934,291, filed Jun. 11, 2007, U.S. Provisional Application No. 60 / 878,831, filed Jan. 5, 2007, European Application No. 07020341.9, filed Oct. 17, 2007, and European Application No. 07000211.8, filed Jan. 5, 2007 are incorporated herein by reference in their entireties.[0002]The content of the electronically submitted sequence listing (Name: 21591900006_sequencelisting_ascii.txt, Size: 46,754 bytes; and Date of Creation: Mar. 13, 2013) is herein incorporated by reference in its entirety.FIELD OF THE INVENTION[0003]The present invention relates to novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize disease-associated epitopes, including neoepitopes, of proteins which derive from native endogenous pro...

AI Technical Summary

Benefits of technology

[0009]Known is the fact that, in case of autoimmune diseases, antibodies are directed against autologous cells and proteins or other compounds such as glycolipids expressed by said cells while evading the known tolerance mechanisms. Also known is the fact that, in case of endogenous neoplastic developments, a cellular and humoral immunity to the neoplastic cells can develop and can thus effect an endogenous immunological protection mechanism against neoplastic tissue degeneration.

Problems solved by technology

However, the therapeutic utility of murine based antibodies in human is hampered by the human anti-mouse antibody (HAMA) response in view of their non-human origin.

However, the methods hitherto available suffer from the drawback that they are not suitable to produce antibodies with the characteristics of those produced in the course of a physiological human immune response.

Furthermore, such antibodies may not be specific enough because of cross-reactivity with other proteins and / or the target protein in context with normal physiological function.

On the other hand, active immunization with pathological relevant antigens bears the considerable risk of patients developing antibodies and T cell responses which also recognize physiological variants of such proteins and in consequence lead to a dangerous and uncontrollable autoimmune response.

Images